Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary

What is this summary about?: Atopic dermatitis (AD, also called atopic eczema) is a skin disease that that can affect a person for a long time and causes red or flaky skin that can be itchy and uncomfortable. Healthcare providers can prescribe medicated creams and ointments to reduce the visible signs and symptoms of AD, but these treatments are not always enough to keep it under control. A new medicine called abrocitinib is taken every day as a tablet. Abrocitinib works by slowing a part of the body's defense mechanism, called immune response, that is not functioning properly in AD. The clinical study described in this plain language summary, called JADE DARE, investigated how well and how safely 26 weeks of treatment with abrocitinib worked in adults with AD compared to an injected medicine, called dupilumab, that is also approved for AD.

What were the results?: The study showed that abrocitinib was more effective than dupilumab in providing itch relief after 2 weeks. In addition, people who were taking abrocitinib for 4 and 16 weeks experienced greater improvement in the visible skin signs of AD than people who were taking dupilumab. The number of people who had health complaints while taking abrocitinib was similar to the number of people who had health complaints while taking dupilumab. Most of these complaints were minor.

What do the results mean?: Abrocitinib was more effective than dupilumab in quickly improving the signs and symptoms of moderate or severe AD in people who did not show improvement with prescribed medications like creams or ointments.

 

Comments:

This summary is about a clinical study called JADE DARE that investigated the effectiveness and safety of a new medicine called abrocitinib in treating atopic dermatitis (AD). AD is a chronic skin disease that causes red, flaky, and itchy skin. Abrocitinib is taken orally as a tablet and works by slowing down the immune response, which is dysfunctional in AD. The study compared abrocitinib to another approved AD medicine called dupilumab. The results showed that abrocitinib provided itch relief more quickly than dupilumab, and people taking abrocitinib experienced greater improvement in the visible skin signs of AD. The number of health complaints while taking abrocitinib was similar to those reported with dupilumab, and most of the complaints were minor. Overall, the results suggest that abrocitinib is more effective than dupilumab in improving the signs and symptoms of moderate to severe AD in individuals who did not respond to topical medications.

Related Products

Cat.No.	Product Name	Information
S8765	Abrocitinib (PF-04965842)	Abrocitinib (PF-04965842) is a potent JAK1 inhibitor with IC50s of 29 nM, 803 nM, > 10 000 nM and 1250 nM for JAK1, JAK2, JAK3 and tyrosine kinase (TYK) 2, respectively.

Related Targets

JAK